南非卫生经济研究的现状。 - Suppr

Suppr

超能文献

The state of health economic research in South Africa.

作者信息

Gow Jeff, Strauss Michael, Whiteside Alan

出版信息

Pharmacoeconomics. 2013 Mar;31(3):251-3. doi: 10.1007/s40273-013-0024-y.

DOI:10.1007/s40273-013-0024-y

PMID:23404128

Abstract

摘要

相似文献

The state of health economic research in South Africa.

Pharmacoeconomics. 2013 Mar;31(3):251-3. doi: 10.1007/s40273-013-0024-y.

The authors' reply to Gow et al.: "the state of health economic research in South Africa".

Pharmacoeconomics. 2013 Mar;31(3):255-6. doi: 10.1007/s40273-013-0027-8.

The state of health economic research in South Africa: a systematic review.

Pharmacoeconomics. 2012 Oct 1;30(10):925-40. doi: 10.2165/11589450-000000000-00000.

Quality of Health Economic Studies (QHES)--tool or mask?

J Manag Care Pharm. 2003 Jan-Feb;9(1):93. doi: 10.18553/jmcp.2003.9.1.93a.

[Health economics: should it concern the health sector?].

Rev Panam Salud Publica. 2002 Nov;12(5):359-65. doi: 10.1590/s1020-49892002001100014.

[Competition success of the pharmaceutical organization study of some factors].

Georgian Med News. 2011 Jun(195):76-9.

Information barriers to the implementation of economic evaluations in Japan.

Pharmacoeconomics. 2002;20 Suppl 2:9-15. doi: 10.2165/00019053-200220002-00002.

The globalization of healthcare...

J Oncol Manag. 1999 Sep-Oct;8(5):4, 6.

PharmacoEconomics. Foreword.

Pharmacoeconomics. 2006 Dec;24 Suppl 2:1-3. doi: 10.2165/00019053-200624002-00001.

ISPOR's Initiative on US Value Assessment Frameworks: Seeking a Role for Health Economics.

Value Health. 2018 Feb;21(2):171-172. doi: 10.1016/j.jval.2017.12.003.

引用本文的文献

The authors' reply to Gow et al.: "the state of health economic research in South Africa".

Pharmacoeconomics. 2013 Mar;31(3):255-6. doi: 10.1007/s40273-013-0027-8.

本文引用的文献

Modelling the relationship between antiretroviral treatment and HIV prevention: limitations of the Spectrum AIDS Impact Model in a changing policy environment.

Afr J AIDS Res. 2007 Aug;6(2):129-37. doi: 10.2989/16085900709490407.

The impact of reduced drug prices on the cost-effectiveness of HAART in South Africa.

Afr J AIDS Res. 2005 May;4(1):65-7. doi: 10.2989/16085900509490343.

The state of health economic and pharmacoeconomic evaluation research in Zimbabwe: A review.

Curr Ther Res Clin Exp. 2008 Jun;69(3):268-85. doi: 10.1016/j.curtheres.2008.06.005.

The state of health economic research in South Africa: a systematic review.

Pharmacoeconomics. 2012 Oct 1;30(10):925-40. doi: 10.2165/11589450-000000000-00000.

The state of health economic evaluation research in Nigeria: a systematic review.

Pharmacoeconomics. 2010;28(7):539-53. doi: 10.2165/11536170-000000000-00000.

Social grants, welfare, and the incentive to trade-off health for income among individuals on HAART in South Africa.

AIDS Behav. 2010 Dec;14(6):1393-400. doi: 10.1007/s10461-009-9642-y.

Estimating the lost benefits of antiretroviral drug use in South Africa.

J Acquir Immune Defic Syndr. 2008 Dec 1;49(4):410-5. doi: 10.1097/qai.0b013e31818a6cd5.

The cost of silence?

Nature. 2008 Dec 4;456(7222):545. doi: 10.1038/456545a.

South Africa's "rollout" of highly active antiretroviral therapy: a critical assessment.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):618-23. doi: 10.1097/01.qai.0000242456.05274.fb.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

The state of health economic research in South Africa.

Pharmacoeconomics. 2013 Mar;31(3):251-3. doi: 10.1007/s40273-013-0024-y.

The authors' reply to Gow et al.: "the state of health economic research in South Africa".

Pharmacoeconomics. 2013 Mar;31(3):255-6. doi: 10.1007/s40273-013-0027-8.

The state of health economic research in South Africa: a systematic review.

Pharmacoeconomics. 2012 Oct 1;30(10):925-40. doi: 10.2165/11589450-000000000-00000.

Quality of Health Economic Studies (QHES)--tool or mask?

J Manag Care Pharm. 2003 Jan-Feb;9(1):93. doi: 10.18553/jmcp.2003.9.1.93a.

[Health economics: should it concern the health sector?].

Rev Panam Salud Publica. 2002 Nov;12(5):359-65. doi: 10.1590/s1020-49892002001100014.

[Competition success of the pharmaceutical organization study of some factors].

Georgian Med News. 2011 Jun(195):76-9.

Information barriers to the implementation of economic evaluations in Japan.

Pharmacoeconomics. 2002;20 Suppl 2:9-15. doi: 10.2165/00019053-200220002-00002.

The globalization of healthcare...

J Oncol Manag. 1999 Sep-Oct;8(5):4, 6.

PharmacoEconomics. Foreword.

Pharmacoeconomics. 2006 Dec;24 Suppl 2:1-3. doi: 10.2165/00019053-200624002-00001.

ISPOR's Initiative on US Value Assessment Frameworks: Seeking a Role for Health Economics.

Value Health. 2018 Feb;21(2):171-172. doi: 10.1016/j.jval.2017.12.003.

引用本文的文献

The authors' reply to Gow et al.: "the state of health economic research in South Africa".

Pharmacoeconomics. 2013 Mar;31(3):255-6. doi: 10.1007/s40273-013-0027-8.

本文引用的文献

Modelling the relationship between antiretroviral treatment and HIV prevention: limitations of the Spectrum AIDS Impact Model in a changing policy environment.

Afr J AIDS Res. 2007 Aug;6(2):129-37. doi: 10.2989/16085900709490407.

The impact of reduced drug prices on the cost-effectiveness of HAART in South Africa.

Afr J AIDS Res. 2005 May;4(1):65-7. doi: 10.2989/16085900509490343.

The state of health economic and pharmacoeconomic evaluation research in Zimbabwe: A review.

Curr Ther Res Clin Exp. 2008 Jun;69(3):268-85. doi: 10.1016/j.curtheres.2008.06.005.

The state of health economic research in South Africa: a systematic review.

Pharmacoeconomics. 2012 Oct 1;30(10):925-40. doi: 10.2165/11589450-000000000-00000.

The state of health economic evaluation research in Nigeria: a systematic review.

Pharmacoeconomics. 2010;28(7):539-53. doi: 10.2165/11536170-000000000-00000.

Social grants, welfare, and the incentive to trade-off health for income among individuals on HAART in South Africa.

AIDS Behav. 2010 Dec;14(6):1393-400. doi: 10.1007/s10461-009-9642-y.

Estimating the lost benefits of antiretroviral drug use in South Africa.

J Acquir Immune Defic Syndr. 2008 Dec 1;49(4):410-5. doi: 10.1097/qai.0b013e31818a6cd5.

The cost of silence?

Nature. 2008 Dec 4;456(7222):545. doi: 10.1038/456545a.

South Africa's "rollout" of highly active antiretroviral therapy: a critical assessment.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):618-23. doi: 10.1097/01.qai.0000242456.05274.fb.